Cancer Family
Malignant Respiratory System Neoplasm
CI-CAN-00000249Explore in graph →
2,650 active trials51 approved drugs619 evidence items
- NCIt
- C4571
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000249Explore in graph →
Clinical trials
11,128 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,492)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00054314 | BAY 59-8862 in Treating Patients With Non-Small Cell Lung Cancer | completed | Phase 2 | — | Roswell Park Cancer InstituteOTHER | 0 | Sep 26, 2022 | clinicaltrials |
| NCT03965845 | A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 53 | Calithera Biosciences, IncINDUSTRY | 1 | Sep 19, 2022 | clinicaltrials |
| NCT00602030 |
| Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC |
| completed |
| Phase 1 / Phase 2 |
| 141 |
| Syndax PharmaceuticalsINDUSTRY |
| 1 |
| Aug 22, 2022 |
| clinicaltrials |
| NCT00970684 | Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 13 | Nathan Pennell, MD, PhDOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT02716311 | Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer(ACE-Lung) | completed | Phase 2 | 118 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT02328105 | LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer | completed | Phase 2 | 11 | Wake Forest University Health SciencesOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT02404441 | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 319 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 3, 2022 | clinicaltrials |
| NCT02945852 | Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy. | completed | Phase 2 | 40 | Fan Yun, MDOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT00553800 | Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) | completed | Phase 2 | 32 | Fox Chase Cancer CenterOTHER | 1 | Jul 12, 2022 | clinicaltrials |
| NCT03623750 | E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C(EPICAL) | completed | Phase 1 / Phase 2 | 23 | Instituto Oncológico Dr RosellOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT04507906 | Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC | completed | Phase 1 / Phase 2 | 21 | Shanghai Chest HospitalOTHER | 1 | Jun 28, 2022 | clinicaltrials |
| NCT00097851 | Trial of PI-88 With Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC) | completed | Phase 2 | 100 | Cellxpert Biotechnology Corp.INDUSTRY | 1 | Jun 27, 2022 | clinicaltrials |
| NCT00103389 | Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 98 | Cellxpert Biotechnology Corp.INDUSTRY | 1 | Jun 27, 2022 | clinicaltrials |
| NCT02920476 | TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003) | completed | Phase 2 | 4 | University of FloridaOTHER | 1 | Jun 23, 2022 | clinicaltrials |
| NCT02648724 | Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies | completed | Phase 1 / Phase 2 | 57 | Symphogen A/SINDUSTRY | 6 | Jun 22, 2022 | clinicaltrials |
| NCT00376623 | Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer | completed | Phase 2 | 96 | Boehringer IngelheimINDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT02183870 | EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer(EUCROSS) | completed | Phase 2 | 34 | University of CologneOTHER | 3 | Jun 16, 2022 | clinicaltrials |
| NCT00979212 | Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer | completed | Phase 2 | 71 | Radiation Therapy Oncology GroupNETWORK | 1 | Jun 15, 2022 | clinicaltrials |
| NCT04636762 | A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 40 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT00750269 | Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 120 | Radiation Therapy Oncology GroupNETWORK | 2 | Jun 9, 2022 | clinicaltrials |
| NCT03717155 | Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC | completed | Phase 2 | 43 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 3 | Jun 6, 2022 | clinicaltrials |
| NCT02684461 | Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel | completed | Phase 2 | 20 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 3, 2022 | clinicaltrials |
| NCT03365791 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | completed | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 1 | May 27, 2022 | clinicaltrials |
| NCT03812809 | A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive | completed | Phase 2 | 226 | Beta Pharma ShanghaiINDUSTRY | 1 | May 19, 2022 | clinicaltrials |
| NCT00887783 | Navelbine And Radiotherapy in Locally Advanced Lung Cancer(NARLAL) | completed | Phase 2 | 117 | Odense University HospitalOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT03386955 | BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 215 | Beta Pharma ShanghaiINDUSTRY | 1 | May 16, 2022 | clinicaltrials |
| NCT00364780 | Study of XL647 in Subjects With Non-Small-Cell Lung Cancer | completed | Phase 2 | 55 | Kadmon Corporation, LLCINDUSTRY | 1 | May 13, 2022 | clinicaltrials |
| NCT00522145 | Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib | completed | Phase 2 | 41 | Kadmon Corporation, LLCINDUSTRY | 1 | May 13, 2022 | clinicaltrials |
| NCT02470468 | Evaluation of Safety and Efficacy of DCVAC/LuCa (Immunotherapy of Lung Cancer) in Patients With Metastatic Lung Cancer | completed | Phase 1 / Phase 2 | 105 | SOTIO a.s.INDUSTRY | 2 | May 4, 2022 | clinicaltrials |
| NCT00456261 | First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC | completed | Phase 2 | 110 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT03268057 | VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer(CLASSICAL-Lung) | completed | Phase 1 / Phase 2 | 62 | Vaccinex Inc.INDUSTRY | 1 | May 2, 2022 | clinicaltrials |
| NCT03562871 | IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC | completed | Phase 1 / Phase 2 | 109 | IO BiotechINDUSTRY | 4 | Apr 21, 2022 | clinicaltrials |
| NCT03633110 | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | completed | Phase 1 / Phase 2 | 24 | Genocea Biosciences, Inc.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT01134250 | Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients | completed | Phase 1 / Phase 2 | 48 | Philogen S.p.A.INDUSTRY | 1 | Apr 15, 2022 | clinicaltrials |
| NCT00152477 | A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer | completed | Phase 2 | 165 | UCB PharmaINDUSTRY | 3 | Apr 12, 2022 | clinicaltrials |
| NCT01003964 | Pharmacogenomic Study for Providing Personalized Strategy to the Treatment of Non-small Cell Lung Cancer (NSCLC) IIIB/IV | completed | Phase 2 | 289 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 12, 2022 | clinicaltrials |
| NCT02347917 | A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma | completed | Phase 1 / Phase 2 | 28 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT01156545 | BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC | completed | Phase 2 | 68 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT02417701 | Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2022 | clinicaltrials |
| NCT02616393 | Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases | completed | Phase 2 | 36 | Kadmon Corporation, LLCINDUSTRY | 1 | Mar 16, 2022 | clinicaltrials |
| NCT01059188 | Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 69 | Swiss Cancer InstituteOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT00600015 | Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC) | completed | Phase 2 | 166 | SCRI Development Innovations, LLCOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT00193414 | Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 72 | SCRI Development Innovations, LLCOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT00193427 | Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer | completed | Phase 2 | 75 | SCRI Development Innovations, LLCOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT03798743 | Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS Study(SUCCESS) | completed | Phase 2 | 30 | Hunan Province Tumor HospitalOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT04144582 | Sintilimab Combined With Docetaxel for Standard Chemotherapy Failure Non-driver Gene Mutation Metastatic Non-small Cell Lung Cancer | completed | Phase 2 | 30 | Yongchang ZhangOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT03794544 | Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer | completed | Phase 2 | 84 | MedImmune LLCINDUSTRY | 7 | Feb 24, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT01935336 | Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers | completed | Phase 2 | 171 | University of Colorado, DenverOTHER | 1 | Feb 11, 2022 | clinicaltrials |
| NCT03088930 | Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer | completed | Phase 2 | 3 | University of Colorado, DenverOTHER | 1 | Feb 11, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Sep 26, 2022source: clinicaltrials